May 15, 2020
AS OPERATORS CONTINUE TO INVEST IN IMPROVED CONNECTIVITY AND PASSENGER EXPERIENCE ON THEIR METRO SYSTEMS, THEY INEVITABLY BECOME MORE EXPOSED TO CYBERSECURITY THREATS. ADELE BERTI ASKS CYLUS CEO AMIR LEVINTAL WHY AND HOW COMPANIES CAN IMPROVE THEIR DEFENCE STRATEGIES.
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002 NEW YORK, Friday August 27, 2021 Read More
MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia June 2, 2021 at 7:0